Thera Card S.R.L.
- Address
- lock Available on a paid plan
Atrial Fibrillation Research
At Thera Card S.R.L. the cardiology team is evaluating a novel antibody to lower stroke risk in patients unsuitable for oral anticoagulants.
- Assess superiority of abelacimab vs placebo for ischemic stroke reduction
- Phase 3 double‑blind LILAC study in high‑risk AF patients
- Focus on individuals unable to use standard oral anticoagulation
The aim is to expand safe treatment options for people with Atrial Fibrillation.
Heart Failure with Reduced Ejection Fraction
Researchers are testing new drug candidates to improve outcomes for individuals with Heart Failure with Reduced Ejection Fraction, focusing on efficacy, safety, and pharmacokinetics.
- Evaluation of JTT‑861 administered for 12 weeks
- Combined safety and tolerability assessment
- Pharmacokinetic profiling in HFrEF subjects
The goal is to identify therapies that lower hospitalization and mortality in heart failure.
Atherosclerotic Cardiovascular Disease and Obesity
A trial at the site examines a GLP‑1‑based agent as an add‑on to standard care, targeting cardiovascular events in overweight patients with ASCVD.
- Maridebart cafraglutide versus placebo as adjunct therapy
- Dual primary endpoints of cardiovascular morbidity and mortality
- Assessment of weight reduction and metabolic impact
Findings could support broader use of metabolic drugs for cardiovascular disease prevention.
Heart Failure and Kidney Impairment
The center studies a combined SGLT2‑based regimen to reduce cardiovascular death and heart‑failure events in patients with reduced kidney function.
- Balcinrenone/dapagliflozin versus dapagliflozin alone
- Effect on cardiovascular death and HF hospitalizations
- Inclusion of patients with recent HF events and renal dysfunction
This research seeks to improve outcomes for a high‑risk subgroup of heart‑failure patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1AstraZeneca AB3active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Thera Card S.R.L.
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 3 | Unknown | 2024-07-12 | 2025-05-06 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.